ReachMD
Be part of the knowledge.™Episodes 1-15 of 83
Case of the Patient in Midlife: Weighing Potential Changes in ASCCP Guidelines
CME/CECase of the Patient in Midlife: Weighing Potential Changes in ASCCP Guidelines
Better Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer
CME/CEBetter Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer
Keeping Pace in Lung Cancer
Personalizing Treatment in NSCLC: Early-Stage Disease (Stage I-IIIa)CME/CEKeeping Pace in Lung Cancer
Personalizing Treatment in NSCLC: Early-Stage Disease (Stage I-IIIa)Keeping Pace in Lung Cancer: Personalizing Treatment in NSCLC: Locally Advanced Disease (Stage IIIB/C)
CME/CEKeeping Pace in Lung Cancer: Personalizing Treatment in NSCLC: Locally Advanced Disease (Stage IIIB/C)
Addressing the Challenge in Rechallenge Strategies for mCRC
CME/CEAddressing the Challenge in Rechallenge Strategies for mCRC
What Is the Evidence Supporting HER2-Targeted TKI-Based Combination Regimens in Metastatic Colorectal Cancer?
Minute CME/CE™What Is the Evidence Supporting HER2-Targeted TKI-Based Combination Regimens in Metastatic Colorectal Cancer?
Expert Panel: Selection and Sequencing HER2-Targeted Therapies for mCRC
Minute CME/CE™Expert Panel: Selection and Sequencing HER2-Targeted Therapies for mCRC
A Look at HER2-Targeted TKIs: How Does Target Specificity Impact Outcomes?
Minute CME/CE™A Look at HER2-Targeted TKIs: How Does Target Specificity Impact Outcomes?
What Are the Clinical Features of HER2 Amplified Colorectal Cancers?
Minute CME/CE™What Are the Clinical Features of HER2 Amplified Colorectal Cancers?
Navigating New Waters in HER2+ mCRC: Selection of the Optimal Targeted Regimen, a Case-Based Approach
Minute CME/CE™Navigating New Waters in HER2+ mCRC: Selection of the Optimal Targeted Regimen, a Case-Based Approach
HER2-Directed TKI Combinations in mCRC: Improving Adherence Through Proactive ADR Monitoring and Management
Minute CME/CE™HER2-Directed TKI Combinations in mCRC: Improving Adherence Through Proactive ADR Monitoring and Management
Why Test for HER2 in Metastatic Colorectal Cancer: From Negative Predictive Biomarker to Emerging Oncotarget
Minute CME/CE™Why Test for HER2 in Metastatic Colorectal Cancer: From Negative Predictive Biomarker to Emerging Oncotarget
Cervical Cancer Screening: The Case of the Young Patient
CME/CECervical Cancer Screening: The Case of the Young Patient
Personalizing the Treatment of Recurrent/Metastatic HNSCC: A Multifactorial Path
CME/CEPersonalizing the Treatment of Recurrent/Metastatic HNSCC: A Multifactorial Path
